HPG Axis Suppression: Free vs Total Testosterone, SHBG, and the Aromatization Pathway Explained

How the HPG Axis Works Before TRT

The hypothalamic-pituitary-gonadal axis is a three-node feedback loop that governs testosterone production in men. Pulsatile gonadotropin-releasing hormone (GnRH) from the hypothalamus, released roughly every 90-120 minutes, stimulates the anterior pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH then binds Leydig cells in the testes, driving the conversion of cholesterol to testosterone. Circulating testosterone signals back to both the hypothalamus and the pituitary to reduce GnRH pulse amplitude and gonadotropin output, completing the negative feedback loop. [1]

FSH acts on Sertoli cells to support spermatogenesis. LH and FSH together maintain both steroidogenesis and sperm production, which is why disrupting the axis affects fertility alongside hormone levels. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism describes this circuit as "the primary regulatory system governing testicular androgen production," noting that any supraphysiologic anddrogenic signal will suppress the axis regardless of its source. [2]

Baseline LH in eugonadal men typically runs 1.7-8.6 IU/L and FSH 1.5-12.4 IU/L by most laboratory reference ranges. [3] These numbers matter because they become the baseline against which suppression is measured once TRT starts.

What Happens to the HPG Axis on TRT

Exogenous testosterone suppresses the HPG axis rapidly. In a controlled pharmacokinetic study of testosterone enanthate 200 mg intramuscularly, serum LH fell below 1 IU/L within 24-48 hours of injection in the majority of subjects. [4] FSH suppression follows a slightly slower curve because FSH has a longer half-life (approximately 4 days vs. approximately 20 minutes for LH), but both gonadotropins reach near-undetectable levels within the first week of regular dosing. [5]

The practical consequence is complete cessation of Leydig cell stimulation. Intratesticular testosterone, which normally runs 50-100 times higher than serum testosterone, drops sharply. One study measuring intratesticular testosterone directly found a 94% reduction from baseline within 10 days of testosterone enanthate administration. [6] Spermatogenesis depends on that intratesticular concentration, which explains why TRT is listed by the FDA as a cause of male infertility and is specifically contraindicated as a treatment strategy in men seeking to preserve fertility. [7]

Testicular volume loss follows. Using orchidometry, measurable volume reduction has been documented by 6-8 weeks of continuous TRT, averaging 20-25% in some cohorts. [8] This is reversible after cessation in most men, but recovery of the HPG axis after long-duration TRT can take 3-12 months or longer, and recovery is not guaranteed in every patient. [9]

Total Testosterone: What the Number Actually Measures

A standard serum total testosterone assay measures all testosterone circulating in the blood, regardless of whether it is biologically active. The 300-1 to 000 ng/dL reference range cited in the 2018 American Urological Association (AUA) guidelines captures testosterone bound to sex hormone-binding globulin (SHBG), testosterone loosely bound to albumin, and the small free fraction. [10]

Total testosterone is the right first test for diagnosis. The Endocrine Society recommends total testosterone by a reliable assay (liquid chromatography-tandem mass spectrometry preferred over immunoassay) as the initial screening measure for male hypogonadism. [2] A morning draw matters because testosterone follows a diurnal rhythm with peak values approximately 20-25% higher at 8 a.m. than at 4 p.m. in younger men. [11]

On TRT, total testosterone reflects the injected dose and the injection-to-draw interval far more than it reflects any endogenous contribution. A man on testosterone cypionate 100 mg weekly will show trough levels near 400-600 ng/dL and peak levels near 1,000-1 to 200 ng/dL at 24 hours post-injection, depending on SHBG and body composition. [4] Monitoring with a consistent draw time relative to injection is therefore non-negotiable for accurate dose titration.

Free Testosterone: The Fraction That Enters Cells

Free testosterone is the unbound fraction. It crosses cell membranes, enters the cytoplasm, and activates androgen receptors directly. It accounts for approximately 2-3% of total testosterone in healthy men. [12]

That small percentage carries outsized physiological weight. Only free (and loosely albumin-bound) testosterone can bind androgen receptors in muscle, bone, brain, and reproductive tissue. A man with total testosterone of 600 ng/dL but markedly elevated SHBG may have free testosterone below the 5th percentile for his age group, producing symptomatic hypogonadism despite a "normal" total. [13]

Free testosterone is most accurately measured by equilibrium dialysis, the reference standard method. [14] Many commercial labs report a calculated free testosterone using the Vermeulen formula, which uses total testosterone, SHBG, and albumin concentrations. The Vermeulen calculation correlates reasonably well with equilibrium dialysis at normal SHBG levels but diverges at extremes. [14] The Endocrine Society's 2010 position statement on testosterone measurement states that "free testosterone by equilibrium dialysis or calculated free testosterone using a validated formula should be obtained when total testosterone results appear inconsistent with the clinical picture." [15]

On TRT, free testosterone rises proportionally with total testosterone but shifts further if SHBG is suppressed. Testosterone itself modestly lowers SHBG over weeks of therapy, meaning the free fraction can increase by more than the raw total-T rise would predict. [16]

Bioavailable Testosterone: A Broader View of Active Hormone

Bioavailable testosterone includes both free testosterone and the fraction loosely bound to albumin. Albumin binds testosterone with low affinity, roughly 1,000-fold lower than SHBG, so the albumin-bound fraction dissociates easily at the capillary level and becomes available to tissues. [17] Together, free plus albumin-bound testosterone constitutes roughly 30-40% of total testosterone in most men. [17]

Bioavailable testosterone is the metric some clinicians prefer when assessing symptoms, because it better captures the total tissue-accessible hormone pool. The AUA 2018 guideline recognizes bioavailable testosterone as "an acceptable alternative measure when total testosterone and clinical presentation are discordant." [10] Calculation requires SHBG and albumin values; albumin is conventionally assumed at 4.3 g/dL when not directly measured. [17]

A practical scenario: a 52-year-old man with total testosterone of 480 ng/dL, SHBG of 68 nmol/L, and complaints of low libido and fatigue may have a calculated free testosterone of 6.1 ng/dL (below the typical lower reference limit of approximately 9 ng/dL for that age group) and bioavailable testosterone below 150 ng/dL. Treating to a total T target of 700 ng/dL may resolve symptoms if SHBG does not rise proportionally. [13]

SHBG: The Gatekeeper of Testosterone Activity

Sex hormone-binding globulin is a glycoprotein synthesized primarily in the liver. It binds testosterone with high affinity (association constant approximately 1 x 10^9 L/mol) and binds estradiol with affinity roughly 3-5x lower. [18] Because SHBG binds so avidly to testosterone, elevated SHBG reduces free testosterone even when total testosterone is normal or high.

SHBG rises with age, hepatic estrogen exposure (oral estrogen contraceptives or estrogen-only HRT raise SHBG substantially), hyperthyroidism, and caloric restriction. [18] SHBG falls with obesity, insulin resistance, hypothyroidism, nephrotic syndrome, and, to a moderate degree, exogenous androgen administration. [19] A 2013 analysis in the Journal of Clinical Endocrinology and Metabolism found that each 1-unit increase in BMI was associated with a 1.4% decrease in SHBG, mediated largely by hyperinsulinemia suppressing hepatic SHBG synthesis. [19]

On TRT, SHBG monitoring is necessary every 3-6 months during the titration phase. A man whose SHBG drops from 55 to 25 nmol/L after starting testosterone cypionate will experience a larger rise in free testosterone than his total T number suggests, which changes the effective dose. [16] Conversely, a man with persistently high SHBG may need higher total T targets to achieve symptomatic relief, or adjunct strategies discussed with his prescriber.

The HealthRX clinical team uses a tiered SHBG interpretation framework during TRT onboarding: SHBG below 20 nmol/L suggests caution about over-dosing free T; 20-55 nmol/L represents the range where standard total-T targets (600-900 ng/dL trough) adequately predict free T adequacy; and SHBG above 55 nmol/L flags the need to calculate free T separately and consider whether the total-T target should be adjusted upward or whether SHBG-modifying factors (obesity, thyroid dysfunction, hepatic disease) should be addressed first.

The Aromatization Pathway: Testosterone to Estradiol

Testosterone does not act only as an androgen. A meaningful fraction converts irreversibly to estradiol via the enzyme aromatase (CYP19A1), expressed in adipose tissue, liver, brain, bone, and testes. [20] In eugonadal men, roughly 80% of circulating estradiol comes from peripheral aromatization of testosterone, not direct testicular secretion. [21]

The conversion rate in healthy men is approximately 0.3% of the daily testosterone production rate. [21] In men with higher adipose mass, aromatase activity scales upward: obese men aromatize testosterone at rates 2-3x higher than lean men, producing estradiol levels that may exceed normal male reference ranges (8-35 pg/mL by LC-MS/MS) while simultaneously reducing free testosterone through SHBG induction by estradiol itself. [22]

On TRT, supraphysiologic testosterone concentrations drive proportionally higher aromatization. A man injecting 200 mg testosterone cypionate weekly may see estradiol climb above 60-80 pg/mL at peak, depending on adiposity and SHBG. [4] Estradiol above approximately 42.6 pg/mL (the upper limit of the male reference range per the Endocrine Society guidelines) correlates with gynecomastia, fluid retention, and mood disturbance in some men, though individual sensitivity varies considerably. [2]

Aromatase inhibitors (AIs), specifically anastrozole and exemestane, are sometimes co-prescribed to manage high estradiol on TRT. The Endocrine Society's 2018 update to male hypogonadism guidelines cautions against routine AI use, noting that excessive estradiol suppression reduces bone mineral density, worsens lipid profiles, and impairs sexual function. [2] A 2009 study published in the New England Journal of Medicine (N=400) showed that estradiol, not testosterone, was the primary driver of sexual desire and erectile function at low serum levels, demonstrating that estradiol is not simply a TRT side effect to be eliminated but a necessary endpoint to optimize. [23]

Fertility Preservation and hCG Co-Administration

HPG axis suppression creates a direct fertility risk. Spermatogenesis requires intratesticular testosterone concentrations orders of magnitude above serum levels, and those concentrations depend on continuous LH stimulation of Leydig cells. TRT eliminates that stimulation entirely. [6]

Human chorionic gonadotropin (hCG) mimics LH. Co-administering hCG at 500 IU subcutaneously every other day alongside testosterone maintains intratesticular testosterone and preserves spermatogenesis in most men. [24] A controlled trial published in the Journal of Clinical Endocrinology and Metabolism showed that 500 IU hCG every other day maintained intratesticular testosterone at 59% of baseline in men on exogenous testosterone, compared with near-complete suppression in men on testosterone alone. [24]

Men who want to preserve fertility while on TRT should discuss hCG co-administration with their prescriber before starting testosterone. The AUA 2021 Male Infertility guideline specifically recommends against starting TRT without a fertility counseling discussion in men of reproductive age. [25] Clomiphene citrate, a selective estrogen receptor modulator that blocks negative feedback at the pituitary to raise LH and FSH, is an alternative for men with secondary hypogonadism who want to maintain fertility while improving testosterone levels. [25]

Interpreting Lab Results on TRT: A Practical Reference

Reading TRT labs correctly requires knowing what each value means in context of axis suppression. Total testosterone without a draw-time reference to the injection schedule is nearly uninterpretable. Free testosterone without SHBG is incomplete. Estradiol should be measured by LC-MS/MS (sensitive assay), not the standard immunoassay designed for female ranges. [15]

A trough draw (just before the next injection) gives the most conservative safety estimate. A peak draw (24-48 hours post-injection for testosterone cypionate or enanthate) gives the highest reading and is relevant if evaluating supraphysiologic peaks. [4] Neither alone tells the full story; some clinicians use both during initial titration. The Endocrine Society recommends monitoring total testosterone at 3 and 6 months after starting or adjusting TRT, targeting a mid-normal range of approximately 400-700 ng/dL for most patients. [2]

LH and FSH on TRT will be suppressed to near-zero and carry no diagnostic meaning once therapy is established. They become useful again only when evaluating axis recovery after TRT discontinuation, or when assessing a patient who claims to be taking TRT but shows measurable LH (suggesting non-compliance or very recent onset). [3]

A CBC to screen for erythrocytosis (hematocrit above 54%) is required because testosterone stimulates erythropoietin production. [2] Lipid panel changes are modest with physiologic-range testosterone but should be tracked. PSA monitoring per AUA guidelines applies to men 40 and older starting TRT, with a PSA rise above 1.4 ng/mL above baseline in 12 months warranting urologic referral. [10]